Malaria, Falciparum Clinical Trial
Official title:
The Tolerability and Safety of Low Dose Primaquine for Transmission Blocking in Symptomatic Falciparum Infected Cambodians
NCT number | NCT02434952 |
Other study ID # | 015NECHR |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | September 11, 2014 |
Last updated | August 22, 2016 |
Start date | October 2014 |
Verified date | August 2016 |
Source | Malaria Consortium |
Contact | n/a |
Is FDA regulated | No |
Health authority | Cambodia: Ministry of Health |
Study type | Interventional |
In Cambodia, falciparum is becoming more difficult to treat because drugs are becoming less
effective. The investigators can help to try to prevent the spread of this resistant malaria
by adding a drug that will make it more difficult for the mosquito to drink up the malaria
in people's blood. If the mosquito cannot drink up the malaria, then the malaria cannot
develop in the mosquito so it will not be able to inject malaria back into people when it
bites. The drug the investigators will use is called primaquine.
Primaquine commonly causes the red cells in the blood to break apart if they are weak. Red
cells need enzymes to work properly and weak red cells have low amounts of an enzyme called
glucose 6 phosphate dehydrogenase (G6PD). The investigators want to know if treating malaria
with primaquine will be safe for the red cells. To do this study, the investigators need to
know if a subject has low G6PD or not.
Status | Completed |
Enrollment | 109 |
Est. completion date | |
Est. primary completion date | July 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 1 Year and older |
Eligibility |
Inclusion Criteria: - Age = 1 year - Presentation with a confirmed fever (= 38°C axilla or = 37.5°C aural) or history of fever in previous 48 hours +/- other clinical features of uncomplicated malaria - Plasmodium falciparum monoinfection = 1 asexual form / 500 white blood cells - Informed consent (written/verbal) provided by patient or relative/legal guardian - Signed Assent form for children aged 12 to < 18 years Exclusion Criteria: - Clinical signs of severe malaria or danger signs - Pregnant or breast feeding - Unable or unwilling to take a pregnancy test (for women of child-bearing age) - Women intending to become pregnant in the next 3 months - Allergic to primaquine or DHA PP - Patients taking drugs known to cause acute intravascular haemolytic anaemia (AIHA) in G6PD deficiency e.g. dapsone, nalidixic acid - Patients on treatment for a significant illness e.g. HIV, tuberculosis (TB) treatment, steroids - On drugs that could interfere with anti-malarial pharmacokinetics like antiretrovirals, cimetidine, ketoconazole, antiepileptic drugs, rifampicin |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Cambodia | Ratanakiri Provincial Hospital | Ratanakiri |
Lead Sponsor | Collaborator |
---|---|
Malaria Consortium | Centers for Disease Control and Prevention, Institute Pasteur, Cambodia, National Centre for Parasitology, Entomology and Malaria Control, Cambodia, World Health Organization |
Cambodia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Haemoglobin concentration | Compare haemoglobin concentrations in g/dL between the G6PD deficient arm given DHA PP plus primaquine, and the G6PD normal arm receiving the same regimen | Day 7 | Yes |
Secondary | Determine G6PD enzyme activity | Quantitative G6PD testing among all participants using the G6PD enzyme assay from Trinity Biologicals, USA, yielding G6PD enzyme results in U/g Hb. | Day 0 | No |
Secondary | Assess usefulness of field adapted WHO haemoglobin colour card vs. Hemocue | Comparison of quantitative (HemoCue, g/dL HB) and qualitative (WHO haemolglobin colour card) estimates of haemoglobin concentration | Day 0 | No |
Secondary | Assess usefulness of rapid test for G6PDd in predicting acute intravascular haemolysis | Comparison of rapid G6PD test (AccessBio, USA) qualitative result against quantitative G6PD assay to determine predictive value for clinically significant haemolysis | Day 0 | No |
Secondary | Proportion patients with =25% change in haemoglobin as a marker of intravascular haemolysis | Comparing across all 4 arms: proportion of all patients with fractional change in haemoglobin =25% from day 0 to day 7 | Change from Day 0 to Day 7 | Yes |
Secondary | Plasma haemoglobin concentration as a marker of intravascular haemolysis | Comparing across all 4 arms: plasma haemoglobin concentration at day 7 | Day 7 | Yes |
Secondary | Urine colour change as a marker of intravascular haemolysis | Change in urine colour grade from day 0 to day 7 (Hillmen, Hall et al. 2004) | Change from Day 0 to Day 7 | Yes |
Secondary | Fractional change in haemoglobin as a marker of intravascular haemolysis | Comparing across all 4 arms: fractional change in haemoglobin on day 7 vs. day 0 | Change from Day 0 to Day 7 | Yes |
Secondary | Clearance rate of primaquine | Primaquine elimination clearance rate, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 | No |
Secondary | Half life of primaquine | Primaquine terminal elimination half life, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 | No |
Secondary | Primaquine volume of distribution | Primaquine apparent volume of distribution (Vd), modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 | No |
Secondary | Clearance rate of piperaquine | Piperaquine elimination clearance rate, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 | No |
Secondary | Half life of piperaquine | Piperaquine terminal elimination half life, modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 | No |
Secondary | Piperaquine volume of distribution | Piperaquine apparent volume of distribution (Vd), modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 | No |
Secondary | Peak plasma concentration (Cmax) of primaquine | Cmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 | No |
Secondary | Peak plasma concentration (Cmax) of piperaquine | Cmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 | No |
Secondary | Time to primquine peak plasma concentration (Tmax) | Tmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 | No |
Secondary | Time to piperaquine peak plasma concentration (Tmax) | Tmax taken directly from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 | No |
Secondary | Area under the plasma concentration versus time curve - primaquine | Modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP + PQ | Day 0-7 | No |
Secondary | Area under the plasma concentration versus time curve - piperaquine | Modelled from population pharmacokinetic data from all patients receiving at least one dose of DHA PP +/- PQ | Day 0-28 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02329301 -
Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia
|
N/A | |
Recruiting |
NCT01944189 -
Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics
|
Phase 4 | |
Completed |
NCT01325974 -
Time to Become Negative of Three Rapid Diagnostic Tests for Malaria
|
N/A | |
Terminated |
NCT01442168 -
Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
|
Phase 1/Phase 2 | |
Terminated |
NCT00374205 -
Randomized Trial on Effectiveness of ACTs in Ghana
|
Phase 4 | |
Completed |
NCT00375128 -
Sporozoite Challenge of Polyprotein Vaccinees
|
Phase 1/Phase 2 | |
Completed |
NCT04609098 -
Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)
|
Phase 2 | |
Completed |
NCT02851108 -
Methylene Blue Against Falciparum Malaria in Burkina Faso
|
Phase 2 | |
Terminated |
NCT02281344 -
MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants
|
Phase 1 | |
Completed |
NCT01213966 -
Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection
|
Phase 2 | |
Completed |
NCT00479206 -
Artemisinin Resistance in Cambodia
|
N/A | |
Completed |
NCT00126906 -
Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi
|
N/A | |
Completed |
NCT01019408 -
Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan
|
Phase 4 | |
Completed |
NCT00529867 -
Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria
|
Phase 4 | |
Completed |
NCT00137553 -
The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children
|
Phase 4 | |
Completed |
NCT02637128 -
In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria
|
Phase 4 | |
Completed |
NCT01222962 -
Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers
|
Phase 1 | |
Unknown status |
NCT00152204 -
The Community Effectiveness of IPTi in Southern Tanzania
|
Phase 3 | |
Terminated |
NCT00084240 -
Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia
|
Phase 2/Phase 3 | |
Completed |
NCT00137514 -
Chloroquine and Amodiaquine for Treatment of Malaria in Children
|
Phase 4 |